Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Single Dose, 2-period Crossover Bioavailability Study of Two Different Polyethylene Glycol Recombinant Human Growth Hormone(PEG-rhGH) Preparations in Chinese Healthy Adult Male Subjects

NCT06385145 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06385145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06385145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Single Dose, 2-period Crossover Bioavailability Study of Two Different Polyethylene Glycol Recombinant Human Growth Hormone(PEG-rhGH) Preparations in Chinese Healthy Adult Male Subjects
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2024
Completion date
March 26, 2025
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric growth hormone deficiency (pghd)